U.S. market Closed. Opens in 7 hours 31 minutes

VNRX | VolitionRx Limited Stock Overview

(Stock Exchange: AMEX)
Day's Range 0.6000 - 0.6300
52 Week Range 0.4300 - 1.2300
Beta 1.08
Implied Volatility 432.23%
IV Rank 100.00%
Day's Volume 36,654
Average Volume 133,479
Shares Outstanding 92,101,500
Market Cap 55,260,900
Sector Healthcare
Industry Medical - Diagnostics & Research
IPO Date 2012-03-02
Valuation
Profitability
Growth
Health
P/E Ratio -1.50
Forward P/E Ratio N/A
EPS -0.40
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 101
Country USA
Website VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX's peers: ECOR, CFMS, EVGN, EOLS, OCX, STRR
*Chart delayed
Analyzing fundamentals for VNRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see VNRX Fundamentals page.

Watching at VNRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on VNRX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙